NL192325C - Waterig, nasaal farmaceutisch preparaat dat dehydroergotamine bevat en sproeitoedieningsinrichting. - Google Patents

Waterig, nasaal farmaceutisch preparaat dat dehydroergotamine bevat en sproeitoedieningsinrichting. Download PDF

Info

Publication number
NL192325C
NL192325C NL8300325A NL8300325A NL192325C NL 192325 C NL192325 C NL 192325C NL 8300325 A NL8300325 A NL 8300325A NL 8300325 A NL8300325 A NL 8300325A NL 192325 C NL192325 C NL 192325C
Authority
NL
Netherlands
Prior art keywords
caffeine
dihydroergotamine
preparation
nasal
preparation according
Prior art date
Application number
NL8300325A
Other languages
English (en)
Dutch (nl)
Other versions
NL192325B (nl
NL8300325A (nl
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of NL8300325A publication Critical patent/NL8300325A/nl
Publication of NL192325B publication Critical patent/NL192325B/xx
Application granted granted Critical
Publication of NL192325C publication Critical patent/NL192325C/nl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NL8300325A 1982-02-01 1983-01-28 Waterig, nasaal farmaceutisch preparaat dat dehydroergotamine bevat en sproeitoedieningsinrichting. NL192325C (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8202781 1982-02-01
GB8202781 1982-02-01

Publications (3)

Publication Number Publication Date
NL8300325A NL8300325A (nl) 1983-09-01
NL192325B NL192325B (nl) 1997-02-03
NL192325C true NL192325C (nl) 1997-06-04

Family

ID=10528017

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8300325A NL192325C (nl) 1982-02-01 1983-01-28 Waterig, nasaal farmaceutisch preparaat dat dehydroergotamine bevat en sproeitoedieningsinrichting.

Country Status (27)

Country Link
JP (1) JPS58134017A (US20100268047A1-20101021-C00004.png)
AT (1) AT385656B (US20100268047A1-20101021-C00004.png)
AU (1) AU565613B2 (US20100268047A1-20101021-C00004.png)
BE (1) BE895750A (US20100268047A1-20101021-C00004.png)
CA (1) CA1197783A (US20100268047A1-20101021-C00004.png)
CH (1) CH653555A5 (US20100268047A1-20101021-C00004.png)
DE (1) DE3302949A1 (US20100268047A1-20101021-C00004.png)
DK (1) DK164771C (US20100268047A1-20101021-C00004.png)
ES (1) ES8502865A1 (US20100268047A1-20101021-C00004.png)
FI (1) FI81258C (US20100268047A1-20101021-C00004.png)
FR (1) FR2539994B1 (US20100268047A1-20101021-C00004.png)
GR (1) GR81320B (US20100268047A1-20101021-C00004.png)
HK (1) HK59989A (US20100268047A1-20101021-C00004.png)
HU (1) HU191512B (US20100268047A1-20101021-C00004.png)
IE (1) IE54532B1 (US20100268047A1-20101021-C00004.png)
IL (1) IL67822A (US20100268047A1-20101021-C00004.png)
IT (1) IT1197558B (US20100268047A1-20101021-C00004.png)
KE (1) KE3888A (US20100268047A1-20101021-C00004.png)
LU (1) LU84613A1 (US20100268047A1-20101021-C00004.png)
MY (1) MY8700766A (US20100268047A1-20101021-C00004.png)
NL (1) NL192325C (US20100268047A1-20101021-C00004.png)
NZ (1) NZ203117A (US20100268047A1-20101021-C00004.png)
PH (1) PH22198A (US20100268047A1-20101021-C00004.png)
PT (1) PT76166B (US20100268047A1-20101021-C00004.png)
SE (1) SE454402B (US20100268047A1-20101021-C00004.png)
SG (1) SG34389G (US20100268047A1-20101021-C00004.png)
ZA (1) ZA83673B (US20100268047A1-20101021-C00004.png)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
GB0910375D0 (en) * 2009-06-16 2009-07-29 Biocopea Ltd Drug composition and its use in therapy
JP7317020B2 (ja) * 2018-01-05 2023-07-28 インペル ファーマシューティカルズ インコーポレイテッド 精密嗅覚デバイスによるジヒドロエルゴタミンの鼻腔内送達

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091569A (en) * 1960-08-26 1963-05-28 Mead Johnson & Co Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus
GB1202885A (en) * 1966-12-22 1970-08-19 Sandoz Ltd Pharmaceutical compositions comprising alkaloids
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
FR2387035A1 (fr) * 1977-04-12 1978-11-10 Cassenne Lab Sa Nouveau medicament destine notamment au traitement des troubles fonctionnels cerebraux
DE2831728C2 (de) * 1978-07-19 1982-12-23 Krewel-Werke Gmbh, 5208 Eitorf Arzneimittel zur Behandlung von Kopfschmerzen

Also Published As

Publication number Publication date
SE454402B (sv) 1988-05-02
ATA30383A (de) 1987-10-15
DE3302949A1 (de) 1983-08-11
FR2539994B1 (fr) 1986-10-10
HK59989A (en) 1989-08-04
SG34389G (en) 1989-09-22
FI81258B (fi) 1990-06-29
FI81258C (fi) 1990-10-10
CA1197783A (en) 1985-12-10
BE895750A (fr) 1983-08-01
ZA83673B (en) 1984-09-26
IE830187L (en) 1983-08-01
AT385656B (de) 1988-05-10
NL192325B (nl) 1997-02-03
IT1197558B (it) 1988-12-06
IL67822A (en) 1988-02-29
JPH0253406B2 (US20100268047A1-20101021-C00004.png) 1990-11-16
PT76166B (en) 1986-02-04
SE8300495L (sv) 1983-08-02
GR81320B (US20100268047A1-20101021-C00004.png) 1984-12-11
PT76166A (en) 1983-02-01
DE3302949C2 (US20100268047A1-20101021-C00004.png) 1992-05-21
DK38183D0 (da) 1983-01-31
HU191512B (en) 1987-02-27
FR2539994A1 (fr) 1984-08-03
LU84613A1 (fr) 1983-09-08
AU1085083A (en) 1983-08-11
AU565613B2 (en) 1987-09-24
MY8700766A (en) 1987-12-31
ES519450A0 (es) 1985-02-01
IL67822A0 (en) 1983-06-15
NZ203117A (en) 1986-12-05
FI830245A0 (fi) 1983-01-25
JPS58134017A (ja) 1983-08-10
IE54532B1 (en) 1989-11-08
ES8502865A1 (es) 1985-02-01
DK164771B (da) 1992-08-17
CH653555A5 (de) 1986-01-15
IT8347646A0 (it) 1983-02-01
PH22198A (en) 1988-06-28
KE3888A (en) 1989-09-01
DK164771C (da) 1992-12-28
NL8300325A (nl) 1983-09-01
DK38183A (da) 1983-08-02
FI830245L (fi) 1983-08-02
SE8300495D0 (sv) 1983-01-31

Similar Documents

Publication Publication Date Title
US5169849A (en) Nasal pharmaceutical compositions
JP6941224B2 (ja) 疾患の処置のための鼻腔内エピネフリン製剤及び方法
RU2421209C2 (ru) Фармацевтические композиции, содержащие циклоспорин
US10751343B2 (en) Nasal compositions stimulating ciliary activity
CA2483917C (en) Formulations limiting spread of pulmonary infections
IL148241A (en) Composition for inhalation containing delta-9-tetrahydrocannabinol
AU2019253137A1 (en) Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos)
NL192325C (nl) Waterig, nasaal farmaceutisch preparaat dat dehydroergotamine bevat en sproeitoedieningsinrichting.
GB2114001A (en) Nasal pharmaceutical compositions
WO1996000071A1 (en) Treatment of nicotine craving and/or smoking withdrawal symptoms with a liquid nasal composition containing nicotine and caffeine or xanthine
AU2021254650B2 (en) Intranasal epinephrine formulations and methods for the treatment of disease

Legal Events

Date Code Title Description
A85 Still pending on 85-01-01
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
SNR Assignments of patents or rights arising from examined patent applications

Owner name: NOVARTIS AG

V4 Discontinued because of reaching the maximum lifetime of a patent

Effective date: 20030128